Abstract
TNF-α is a pleiotropic cytokine with strong proinflammatory and immunomodulatory properties. TNF-α plays a critical role in many acute or chronic inflammatory diseases and anti-TNFstrategies have proven to be clinically effective. Two TNF-specific cell surface receptors TNF-R1 and TNF-R2 have been identified and the function of these receptors and the downstream intracellular signal transduction pathways have been extensively studied in vitro. For a long time TNF-R1 was considered to be the predominant mediator of TNF-signaling, whereas TNF-R2 was ascribed only auxilliary function. However, there is increasing clinical and experimental evidence for an important independent role of p80 signaling in chronic inflammatory conditions. It is conceivable that the multiple TNF-mediated chronic inflammatory disorders differ in terms of the ligand form (soluble TNF-α versus membrane bound TNF-α), the receptor (TNF-R1 versus TNF-R2) and the downstream signaling cascades utilized. The elucidation of the specific characteristics of TNF-signaling in distinct inflammatory disorders will lead to a better understanding ot the pathogenesis of these diseases and will be the basis for the development of more specific and more efficient therapeutic approaches.
Keywords: tnf, tnf-r2, signal transduction, inflammatory disorders
Current Molecular Medicine
Title: Differential TNF-Signaling in Chronic Inflammatory Disorders
Volume: 4 Issue: 4
Author(s): Martin H. Holtmann and Markus F. Neurath
Affiliation:
Keywords: tnf, tnf-r2, signal transduction, inflammatory disorders
Abstract: TNF-α is a pleiotropic cytokine with strong proinflammatory and immunomodulatory properties. TNF-α plays a critical role in many acute or chronic inflammatory diseases and anti-TNFstrategies have proven to be clinically effective. Two TNF-specific cell surface receptors TNF-R1 and TNF-R2 have been identified and the function of these receptors and the downstream intracellular signal transduction pathways have been extensively studied in vitro. For a long time TNF-R1 was considered to be the predominant mediator of TNF-signaling, whereas TNF-R2 was ascribed only auxilliary function. However, there is increasing clinical and experimental evidence for an important independent role of p80 signaling in chronic inflammatory conditions. It is conceivable that the multiple TNF-mediated chronic inflammatory disorders differ in terms of the ligand form (soluble TNF-α versus membrane bound TNF-α), the receptor (TNF-R1 versus TNF-R2) and the downstream signaling cascades utilized. The elucidation of the specific characteristics of TNF-signaling in distinct inflammatory disorders will lead to a better understanding ot the pathogenesis of these diseases and will be the basis for the development of more specific and more efficient therapeutic approaches.
Export Options
About this article
Cite this article as:
Holtmann H. Martin and Neurath F. Markus, Differential TNF-Signaling in Chronic Inflammatory Disorders, Current Molecular Medicine 2004; 4 (4) . https://dx.doi.org/10.2174/1566524043360636
DOI https://dx.doi.org/10.2174/1566524043360636 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-β2-Glycoprotein I Antibodies in Lyme Borreliosis: Differences in Disease Stage and Immunoglobulin Class Distribution
Current Rheumatology Reviews Meta-Analysis of Anticancer Drug Structures - Significance of Their Polar Allylic Moieties
Anti-Cancer Agents in Medicinal Chemistry Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
Current Drug Targets The Potential of Modulating Small RNA Activity In Vivo
Mini-Reviews in Medicinal Chemistry Chemical and physical factors influencing the dynamics of differentiation in embryonic stem cells
Current Stem Cell Research & Therapy Astrocyte-Microglia Cooperation in the Expression of a Pro-Inflammatory Phenotype
CNS & Neurological Disorders - Drug Targets The Antiplatelet and Antithrombotic Actions of Statins
Current Pharmaceutical Design Sugar-Borate Esters – Potential Chemical Agents in Prostate Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry A Role for Insulin on L-Arginine Transport in Fetal Endothelial Dysfunction in Hyperglycaemia
Current Vascular Pharmacology NK Cell Function in HIV-1 Infection
Current HIV Research QSAR of Pyrazole Oxadiazole Derivatives as s1p1 Agonists Studied by CoMFA, CoMSIA and Docking
Letters in Drug Design & Discovery Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology TP Receptor as a Therapeutic Target in Atherosclerosis and Related Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Current Medicinal Chemistry A Study of Extrapyramidal Manifestations Accompanying Decompensated Viral Hepatic Cirrhosis Patients
Reviews on Recent Clinical Trials Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Computer-Aided Drug Discovery and Design Targeting Ion Channels
Current Topics in Medicinal Chemistry HIV-1, HCV and Alcohol in the CNS: Potential Interactions and Effects on Neuroinflammation
Current HIV Research Drug Targets in Stress-Related Disorders
Current Medicinal Chemistry Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology